Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels. The FDA approved Vascepa to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe under the tradename of Vazkepa. It has initiated various promotional activities and direct-to-consumer programs as well as expanded its salesforce to support promotion of Vascepa's expanded label. A generic version of Vascepa has been launched for elevated TG levels....
+See More2023-11-21 11:32:00 Tuesday ET
Nobel Laureate Paul Milgrom explains the U.S. incentive auction of wireless spectrum allocation from TV broadcasters to telecoms. Paul Milgrom (2019)
2017-08-31 09:36:00 Thursday ET
The Trump administration has initiated a new investigation into China's abuse of American intellectual property under Section 301 of the Trade Act of 19
2023-10-21 11:32:00 Saturday ET
Walter Scheidel indicates that persistent European fragmentation after the collapse of the Roman Empire leads to modern economic growth and development.
2019-08-18 11:33:00 Sunday ET
House Judiciary Committee summons senior executive reps of the tech titans to assess online platforms and their market power. These companies are Facebook,
2022-03-25 09:34:00 Friday ET
Corporate cash management The empirical corporate finance literature suggests four primary motives for firms to hold cash. These motives include the tra
2017-11-03 06:41:00 Friday ET
Broadcom, a one-time division of Hewlett-Packard and now a semiconductor maker whose chips help power iPhone X, has announced its strategic plans to move it